DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis

De Wei Wu, Po Lin Lin, Ya Wen Cheng, Chi Chou Huang, Lee Wang, Huei Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

DDX3 plays a dual role in colorectal cancer; however, the role and underlying mechanism of DDX3 in colorectal tumorigenesis remains unclear. Here, we provide evidence that DDX3 enhances oncogenic KRAS transcription via an increase in SP1 binding to its promoter. Accelerating oncogenic KRAS expression by DDX3 promotes the invasion capability via the ERK/PTEN/AKT/β-catenin cascade. Moreover, the β-catenin/ZEB1 axis is responsible for DDX3-induced cell invasiveness and xenograft lung tumor nodule formation. The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or β-catenin (XAV939). Among patients, high KRAS, positive nuclear β-catenin expression and high ZEB1 were more commonly occurred in high-DDX3 tumors than in low-DDX3 tumors. High-DDX3, high-KRAS, positive nuclear β-catenin tumors, and high-ZEB1 exhibited worse overall survival (OS) and relapse free survival (RFS) than their counterparts. In conclusion, DDX3 may play an oncogenic role to promote tumor growth and invasion in colon cancer cells via the β-catenin/ZEB1 axis due to increasing KRAS transcription. We therefore suggest that AKT or β-catenin may potentially act as a therapeutic target to improve tumor regression and outcomes in colorectal cancer patients who harbored high-DDX3 tumors.

Original languageEnglish
Pages (from-to)22687-22699
Number of pages13
JournalOncotarget
Volume7
Issue number16
DOIs
Publication statusPublished - Apr 19 2016

Fingerprint

Catenins
Colorectal Neoplasms
Neoplasms
Heterografts
Lung
Survival
Colonic Neoplasms
Carcinogenesis
Clone Cells
Recurrence
Growth

Keywords

  • AKT
  • Colorectal cancer
  • DDX3
  • KRAS
  • β-catenin

ASJC Scopus subject areas

  • Oncology

Cite this

Wu, D. W., Lin, P. L., Cheng, Y. W., Huang, C. C., Wang, L., & Lee, H. (2016). DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis. Oncotarget, 7(16), 22687-22699. https://doi.org/10.18632/oncotarget.8143

DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis. / Wu, De Wei; Lin, Po Lin; Cheng, Ya Wen; Huang, Chi Chou; Wang, Lee; Lee, Huei.

In: Oncotarget, Vol. 7, No. 16, 19.04.2016, p. 22687-22699.

Research output: Contribution to journalArticle

Wu, DW, Lin, PL, Cheng, YW, Huang, CC, Wang, L & Lee, H 2016, 'DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis', Oncotarget, vol. 7, no. 16, pp. 22687-22699. https://doi.org/10.18632/oncotarget.8143
Wu, De Wei ; Lin, Po Lin ; Cheng, Ya Wen ; Huang, Chi Chou ; Wang, Lee ; Lee, Huei. / DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis. In: Oncotarget. 2016 ; Vol. 7, No. 16. pp. 22687-22699.
@article{48282f202a664c6992027414b515731b,
title = "DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis",
abstract = "DDX3 plays a dual role in colorectal cancer; however, the role and underlying mechanism of DDX3 in colorectal tumorigenesis remains unclear. Here, we provide evidence that DDX3 enhances oncogenic KRAS transcription via an increase in SP1 binding to its promoter. Accelerating oncogenic KRAS expression by DDX3 promotes the invasion capability via the ERK/PTEN/AKT/β-catenin cascade. Moreover, the β-catenin/ZEB1 axis is responsible for DDX3-induced cell invasiveness and xenograft lung tumor nodule formation. The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or β-catenin (XAV939). Among patients, high KRAS, positive nuclear β-catenin expression and high ZEB1 were more commonly occurred in high-DDX3 tumors than in low-DDX3 tumors. High-DDX3, high-KRAS, positive nuclear β-catenin tumors, and high-ZEB1 exhibited worse overall survival (OS) and relapse free survival (RFS) than their counterparts. In conclusion, DDX3 may play an oncogenic role to promote tumor growth and invasion in colon cancer cells via the β-catenin/ZEB1 axis due to increasing KRAS transcription. We therefore suggest that AKT or β-catenin may potentially act as a therapeutic target to improve tumor regression and outcomes in colorectal cancer patients who harbored high-DDX3 tumors.",
keywords = "AKT, Colorectal cancer, DDX3, KRAS, β-catenin",
author = "Wu, {De Wei} and Lin, {Po Lin} and Cheng, {Ya Wen} and Huang, {Chi Chou} and Lee Wang and Huei Lee",
year = "2016",
month = "4",
day = "19",
doi = "10.18632/oncotarget.8143",
language = "English",
volume = "7",
pages = "22687--22699",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",

}

TY - JOUR

T1 - DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β-catenin/ZEB1 axis

AU - Wu, De Wei

AU - Lin, Po Lin

AU - Cheng, Ya Wen

AU - Huang, Chi Chou

AU - Wang, Lee

AU - Lee, Huei

PY - 2016/4/19

Y1 - 2016/4/19

N2 - DDX3 plays a dual role in colorectal cancer; however, the role and underlying mechanism of DDX3 in colorectal tumorigenesis remains unclear. Here, we provide evidence that DDX3 enhances oncogenic KRAS transcription via an increase in SP1 binding to its promoter. Accelerating oncogenic KRAS expression by DDX3 promotes the invasion capability via the ERK/PTEN/AKT/β-catenin cascade. Moreover, the β-catenin/ZEB1 axis is responsible for DDX3-induced cell invasiveness and xenograft lung tumor nodule formation. The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or β-catenin (XAV939). Among patients, high KRAS, positive nuclear β-catenin expression and high ZEB1 were more commonly occurred in high-DDX3 tumors than in low-DDX3 tumors. High-DDX3, high-KRAS, positive nuclear β-catenin tumors, and high-ZEB1 exhibited worse overall survival (OS) and relapse free survival (RFS) than their counterparts. In conclusion, DDX3 may play an oncogenic role to promote tumor growth and invasion in colon cancer cells via the β-catenin/ZEB1 axis due to increasing KRAS transcription. We therefore suggest that AKT or β-catenin may potentially act as a therapeutic target to improve tumor regression and outcomes in colorectal cancer patients who harbored high-DDX3 tumors.

AB - DDX3 plays a dual role in colorectal cancer; however, the role and underlying mechanism of DDX3 in colorectal tumorigenesis remains unclear. Here, we provide evidence that DDX3 enhances oncogenic KRAS transcription via an increase in SP1 binding to its promoter. Accelerating oncogenic KRAS expression by DDX3 promotes the invasion capability via the ERK/PTEN/AKT/β-catenin cascade. Moreover, the β-catenin/ZEB1 axis is responsible for DDX3-induced cell invasiveness and xenograft lung tumor nodule formation. The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or β-catenin (XAV939). Among patients, high KRAS, positive nuclear β-catenin expression and high ZEB1 were more commonly occurred in high-DDX3 tumors than in low-DDX3 tumors. High-DDX3, high-KRAS, positive nuclear β-catenin tumors, and high-ZEB1 exhibited worse overall survival (OS) and relapse free survival (RFS) than their counterparts. In conclusion, DDX3 may play an oncogenic role to promote tumor growth and invasion in colon cancer cells via the β-catenin/ZEB1 axis due to increasing KRAS transcription. We therefore suggest that AKT or β-catenin may potentially act as a therapeutic target to improve tumor regression and outcomes in colorectal cancer patients who harbored high-DDX3 tumors.

KW - AKT

KW - Colorectal cancer

KW - DDX3

KW - KRAS

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84965064082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965064082&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8143

DO - 10.18632/oncotarget.8143

M3 - Article

C2 - 27007150

AN - SCOPUS:84965064082

VL - 7

SP - 22687

EP - 22699

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -